Jinyu Bio-Technology Co Total Assets
The Total Assets of Jinyu Bio-Technology Co (600201.SS) as of Sep 12, 2026 is 6.76 B CNY. In the previous year, Total Assets was 6.87 B CNY — a change of -1.57% (lower).
Get this data via API
Financial Data API
Total Assets
6.76 BCNY
YoY
-1.57%
Last updated:
The Jinyu Bio-Technology Co Total Assets history
3 Years
10 Years
25 Years
Max
| YEAR | Total Assets | YoY |
|---|---|---|
| 6.76 BCNY | -1.57% | |
| 6.87 BCNY | +7.56% | |
| 6.39 BCNY | -3.25% | |
| 6.60 BCNY | +5.19% | |
| 6.28 BCNY | +12.40% | |
| 5.59 BCNY | -11.52% | |
| 6.31 BCNY | +11.08% | |
| 5.68 BCNY | +30.73% | |
| 4.35 BCNY | +70.48% | |
| 2.55 BCNY | +21.55% | |
| 2.10 BCNY | — |
Jinyu Bio-Technology Co Stock analysis
Frequently Asked Questions about Jinyu Bio-Technology Co stock
Total Assets of Jinyu Bio-Technology Co is 6.76 B CNY in 2026.
Total Assets of Jinyu Bio-Technology Co changed from 6.87 B CNY to 6.76 B CNY, representing a -1.57% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Total Assets Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.
Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Jinyu Bio-Technology Co historically and in real time.
Balance Sheet — Jinyu Bio-Technology Co
All Key Metrics — Jinyu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth